Abstract
Significant progress have been made in the management of obesity thanks to the emergence of effective drug treatments, combined with dietary advice and regular physical activity. Unlike previous drugs tested, these new therapies allow for significant weight loss without serious side effects. They act primarily by increasing feelings of satiety and reducing food intake without frustration. GLP1 receptor agonists, such as liraglutide and semaglutide, are already recommended therapeutic options for the management of obesity in France. This review examines the mechanisms, efficacy, and side effects of the main drugs currently available on prescription.© 2023 Société francophone nutrition clinique et métabolisme (SFNCM).Published by Elsevier Masson SAS. All rights reserved.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
